These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17658374)

  • 21. Effect of add-on aliskiren to type 1 angiotensin receptor blocker therapy on endothelial function and autonomic nervous system in hypertensive patients with ischemic heart disease.
    Ozeki A; Amiya E; Watanabe M; Hosoya Y; Takata M; Watanabe A; Kawarasaki S; Nakao T; Watanabe S; Omori K; Yamada N; Tahara Y; Hirata Y; Nagai R
    J Clin Hypertens (Greenwich); 2014 Aug; 16(8):591-8. PubMed ID: 25039889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of aliskiren and valsartan in hypertensive patients with albuminuria: a randomized parallel-group study.
    Spanos G; Kalaitzidis R; Karasavvidou D; Pappas K; Siamopoulos KC
    J Renin Angiotensin Aldosterone Syst; 2013 Dec; 14(4):315-21. PubMed ID: 23132848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].
    Dralova OV; Maksimov ML; Derbentseva EA; Ermolaeva AS; Starodubtsev AK
    Eksp Klin Farmakol; 2011; 74(4):14-7. PubMed ID: 21678653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise.
    Williams B; Baschiera F; Lacy PS; Botha J; Prescott MF; Brunel P
    J Renin Angiotensin Aldosterone Syst; 2013 Mar; 14(1):56-66. PubMed ID: 22859712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
    J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin II type 1 receptor blockers.
    Burnier M
    Circulation; 2001 Feb; 103(6):904-12. PubMed ID: 11171802
    [No Abstract]   [Full Text] [Related]  

  • 28. Aliskiren, the future of renin-angiotensin system blockade?
    Uresin Y; Mehtar Bozkurt M; Sabirli S; Ozunal ZG
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):835-49. PubMed ID: 17867914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
    Wang W; Qiu L; Howard A; Solis N; Li C; Wang X; Kopp JB; Levi M
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):384-95. PubMed ID: 25031296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S; Valencia J; Kemp C; Zhao C; Yeh CM; Bizot MN; Denouel J; Dieterich HA; Dole WP
    Int J Clin Pract; 2006 Nov; 60(11):1343-56. PubMed ID: 17073832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
    J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Renin inhibition in hypertension].
    Güleç S
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():15-22. PubMed ID: 20019472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Renin inhibition and the kidney].
    Ecder T
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors.
    Yong QC; Thomas CM; Seqqat R; Chandel N; Baker KM; Kumar R
    Cardiovasc Diabetol; 2013 Nov; 12():169. PubMed ID: 24215514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-angiotensin therapy: new perspectives.
    Ramasubbu K; Mann DL; Deswal A
    Cardiol Clin; 2007 Nov; 25(4):573-80; vi-vii. PubMed ID: 18063161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
    Nussberger J; Aubert JF; Bouzourene K; Pellegrin M; Hayoz D; Mazzolai L
    Hypertension; 2008 May; 51(5):1306-11. PubMed ID: 18391092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M; Simioni N; Masiero A
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aliskiren/valsartan (Valturna) for hypertension.
    Med Lett Drugs Ther; 2009 Nov; 51(1326):94-5. PubMed ID: 20224524
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.